How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

21,481 results for

Acute Leukemia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

8. Initial Diagnostic Work-Up of Acute Leukemia

Initial Diagnostic Work-Up of Acute Leukemia Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES February, 05 2019 ARTICLE CITATION DOI: 10.1200/JCO.18.01468 Journal of Clinical Oncology - published online before print December 3, 2018 PMID (...) : Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline , PhD 1 x Valérie de Haas ; , MD 2 x Nofisat Ismaila ; , MD 3 x Anjali Advani ; , MD 4 x Daniel A. Arber ; , MD 5 x Raetasha S. Dabney ; , MD 6 x Dipti Patel-Donelly ; , LMSW 7 x Elizabeth Kitlas ; , MD, PhD 1 x Rob Pieters ; , MD 8 x Ching-Hon Pui ; , MD 9 x Kendra Sweet ; and , MD 9 x Ling Zhang 1Princess Máxima Center

2019 American Society of Clinical Oncology Guidelines

9. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party. (PubMed)

Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party. Copyright © 2019, Ferrata Storti Foundation.

Full Text available with Trip Pro

2019 Haematologica

10. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and (PubMed)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Limited data is available to guide the choice of the conditioning regimen for patients with acute myeloid leukemia (AML) undergoing transplant with persistent disease.We retrospectively compared outcome of fludarabine-treosulfan (FT), thiotepa (...) -busulfan-fludarabine (TBF), and sequential fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide (FLAMSA) conditioning in patients with refractory or relapsed AML.Complete remission rates at day 100 were 92%, 80%, and 88% for FT, TBF, and FLAMSA, respectively (p = 0.13). Non-relapse mortality, incidence of relapse, acute (a) and chronic (c) graft-versus-host disease (GVHD) rates did not differ between the three groups. Overall survival at 2 years was 37

Full Text available with Trip Pro

2019 Journal of hematology & oncology

11. Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. (PubMed)

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia is a common high-risk feature referred to allogeneic stem cell transplantation. However, -5/5q- is frequently associated with other high-risk cytogenetic aberrations such as complex karyotype, monosomal karyotype, monosomy 7 (-7), or 17p abnormalities (abn (...) (17p)), the significance of which is unknown. In order to address this question, we studied adult patients with acute myeloid leukemia harboring -5/5q- having their first allogeneic transplantation between 2000 and 2015. Five hundred and one patients with -5/5q- have been analyzed. Three hundred thirty-eight patients (67%) were in first remission and 142 (28%) had an active disease at time of allogeneic transplantation. The 2-year probabilities of overall survival and leukemia-free survival were 27

Full Text available with Trip Pro

2019 Haematologica

12. Clinical course of sepsis in children with acute leukemia admitted to the pediatric intensive care unit

Clinical course of sepsis in children with acute leukemia admitted to the pediatric intensive care unit PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2017 PedsCCM Evidence-Based Journal Club

13. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia (PubMed)

Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia 28057736 2018 08 06 2018 11 13 1592-8721 102 4 2017 04 Haematologica Haematologica Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia. e125-e128 10.3324/haematol.2016.156844 Martin-Cabrera Pedro P MLL Munich Leukemia Laboratory (...) Suppressor Protein p53 E1UOL152H7 Iron IM Acute Disease Adult Aged Aged, 80 and over Bone Marrow metabolism pathology Cohort Studies Erythroblasts metabolism pathology Female Gene Expression Profiling Gene Expression Regulation High-Throughput Nucleotide Sequencing Humans Iron metabolism Leukemia, Myeloid, Acute genetics metabolism mortality pathology Male Middle Aged Mutation Myelodysplastic Syndromes genetics metabolism mortality pathology Neoplasm Proteins genetics metabolism Neoplasms, Second Primary

Full Text available with Trip Pro

2017 Haematologica

14. Besponsa for Acute Lymphoblastic Leukemia – Details

Besponsa for Acute Lymphoblastic Leukemia – Details Besponsa for Acute Lymphoblastic Leukemia – Details | CADTH.ca Find the information you need Besponsa for Acute Lymphoblastic Leukemia – Details Besponsa for Acute Lymphoblastic Leukemia – Details Project Number pCODR 10121 Brand Name Besponsa Generic Name Inotuzumab Ozogamicin Strength 0.9 mg/vial Tumour Type Leukemia Indication Acute Lymphoblastic Leukemia (ALL) Funding Request For the treatment of relapsed or refractory B-cell precursor (...) acute lymphoblastic leukemia (ALL) Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date March 15, 2018 Manufacturer Pfizer Canada Inc. Submitter Pfizer Canada Inc. Submission Date November 13, 2017 Submission Deemed Complete November 20, 2017 Submission Type New Drug Prioritization Requested Not Requested Stakeholder Input Deadline ‡ November 27, 2017 Check-point meeting January 25, 2018 pERC Meeting April 19, 2018 Initial Recommendation Issued May 3, 2018 Feedback Deadline

2018 CADTH - Pan Canadian Oncology Drug Review

15. Rydapt for Acute Myeloid Leukemia – Details

Rydapt for Acute Myeloid Leukemia – Details Rydapt for Acute Myeloid Leukemia – Details | CADTH.ca Find the information you need Rydapt for Acute Myeloid Leukemia – Details Rydapt for Acute Myeloid Leukemia – Details Project Number pCODR 10108 Brand Name Rydapt Generic Name Midostaurin Strength 25 mg Tumour Type Leukemia Indication Acute Myeloid Leukemia Funding Request In combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment (...) of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date July 21, 2017 Manufacturer Novartis Pharmaceuticals Canada Inc. Submitter Novartis Pharmaceuticals Canada Inc. Submission Date June 12, 2017 Submission Deemed Complete June 19, 2017 Submission Type New Drug Prioritization Requested Requested and Granted Stakeholder Input Deadline ‡ June 26, 2017 Check-point meeting September 26, 2017 pERC

2018 CADTH - Pan Canadian Oncology Drug Review

16. Acute lymphoblastic leukemia

Acute lymphoblastic leukemia CLINICAL PRACTICE GUIDELINE LYHE-005 Version 1 Page 1 of 70 Acute Lymphoblastic Leukemia Effective Date: July, 2016 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment (...) . Refractory ALL: 4.5.1. Transplant eligible patients should be treated with a non-cross resistant re- induction chemotherapy regimen or immunotherapy (if available). 4.5.2. Immunotherapy is recommended for patients who have failed two different chemotherapy regimens. 4.5.3. Transplant eligible patients should be considered for allogeneic HSCT. CLINICAL PRACTICE GUIDELINE LYHE-005 Version 1 Page 9 of 70 OVERVIEW Acute Lymphoblastic Leukemia (ALL) is a highly aggressive hematological - malignancy resulting

2016 CPG Infobase

17. Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBPα to prevent Trib1-driven acute myeloid leukemia (PubMed)

Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBPα to prevent Trib1-driven acute myeloid leukemia C/EBPα is a key transcription factor regulating myeloid differentiation and leukemogenesis. The Trib1-COP1 complex is an E3 ubiquitin ligase that targets C/EBPα for degradation, and its overexpression specifically induces acute myeloid leukemia (AML). Here we show that myeloid leukemia factor 1 (MLF1) stabilizes C/EBPα protein levels by inhibiting the ligase activity of the Trib1-COP1 (...) ) in normal hematopoiesis, which is consistent with the distribution of C/EBPα. An MLF1 deficiency conferred a more immature phenotype on Trib1-induced AML development. A higher expression ratio of Trib1 to MLF1 was a key determinant for AML development in mouse models, which was also confirmed in human patient samples with acute leukemia. These results indicate that MLF1 is a positive regulator that is critical for C/EBPα stability in the early phases of hematopoiesis and leukemogenesis.

Full Text available with Trip Pro

2017 Blood advances

18. Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase (PubMed)

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase The ataxia telangiectasia and Rad3-related (ATR) protein kinase promotes cancer cell survival by signaling stalled replication forks generated by replication stress, a common feature of many cancers including acute myeloid leukemia (AML). Here we show that the antileukemic activity of the chemotherapeutic nucleoside analogs hydroxyurea and gemcitabine was significantly (...) potentiated by ATR inhibition via a mechanism involving ribonucleotide reductase (RNR) abrogation and inhibition of replication fork progression. When administered in combination with gemcitabine, an inhibitor of the M1 RNR subunit, the ATR inhibitor VX-970, eradicated disseminated leukemia in an orthotopic mouse model, eliciting long-term survival and effective cure. These data identify a synergistic interaction between ATR inhibition and RNR loss that will inform the deployment of small molecule

Full Text available with Trip Pro

2018 Blood advances

19. Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (pediatric) – Details

Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (pediatric) – Details Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (pediatric) – Details | CADTH.ca Find the information you need Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (pediatric) – Details Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (pediatric) – Details Project Number pCODR 10099 Brand Name Blincyto Generic Name Blinatumomab Strength 38.5mcg vial Tumour Type Leukemia Indication Pediatric Acute (...) Lymphoblastic Leukemia (ALL) Funding Request For the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B precursor acute lymphoblastic leukemia (ALL) Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date April 28, 2017 Manufacturer Amgen Canada Inc. Submitter Amgen Canada Inc. Submission Date February 24, 2017 Submission Deemed Complete March 3, 2017 Submission Type New Indication Prioritization Requested Requested and Not Granted

2017 CADTH - Pan Canadian Oncology Drug Review

20. Rituxan for Acute Lymphoblastic Leukemia – Details

Rituxan for Acute Lymphoblastic Leukemia – Details Rituxan for Acute Lymphoblastic Leukemia – Details | CADTH.ca Find the information you need Rituxan for Acute Lymphoblastic Leukemia – Details Rituxan for Acute Lymphoblastic Leukemia – Details Project Number pCODR 10102 Brand Name Rituxan Generic Name Rituximab Strength 200mg and 500mg vials Tumour Type Leukemia Indication Acute Lymphoblastic Leukemia Funding Request In combination with standard of care chemotherapy for Philadelphia chromosome (...) negative, CD20 antigen positive, B-cell precursor acute lymphoblastic leukemia in adults Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date N/A Manufacturer Hoffmann-La Roche Limited Submitter Cancer Care Manitoba Submission Date February 13, 2017 Submission Deemed Complete February 21, 2017 Submission Type New Drug Prioritization Requested Not Requested Stakeholder Input Deadline ‡ February 28, 2017 Check-point meeting April 12, 2017 pERC Meeting June 15, 2017 Initial

2017 CADTH - Pan Canadian Oncology Drug Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>